Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.
Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Sota J, Vannozzi L, di Scala G, Guerriero S, Orlando I, Franceschini R, Capozzoli M, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L. Fabiani C, et al. Among authors: orlando i. Clin Rheumatol. 2018 Jun;37(6):1715-1720. doi: 10.1007/s10067-018-4092-4. Epub 2018 Apr 18. Clin Rheumatol. 2018. PMID: 29671190
Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, Orlando I, Franceschini R, Bacherini D, Cimino L, Soriano A, Frediani B, Galeazzi M, Iannone F, Tosi GM, Salvarani C, Cantarini L. Fabiani C, et al. Among authors: orlando i. Clin Rheumatol. 2017 Jan;36(1):183-189. doi: 10.1007/s10067-016-3480-x. Epub 2016 Nov 16. Clin Rheumatol. 2017. PMID: 27853889
Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.
Fabiani C, Sota J, Vitale A, Emmi G, Vannozzi L, Bacherini D, Lopalco G, Guerriero S, Venerito V, Orlando I, Franceschini R, Fusco F, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L. Fabiani C, et al. Among authors: orlando i. Ocul Immunol Inflamm. 2019;27(1):34-39. doi: 10.1080/09273948.2017.1391297. Epub 2017 Nov 3. Ocul Immunol Inflamm. 2019. PMID: 29099660
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis.
Fabiani C, Vitale A, Emmi G, Bitossi A, Lopalco G, Sota J, Guerriero S, Orlando I, Capozzoli M, Fusco F, Rana F, Iannone F, Frediani B, Galeazzi M, Vannozzi L, Tosi GM, Cantarini L. Fabiani C, et al. Among authors: orlando i. Clin Rheumatol. 2019 Jan;38(1):63-70. doi: 10.1007/s10067-018-4069-3. Epub 2018 Apr 3. Clin Rheumatol. 2019. PMID: 29611087
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies.
Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Bitossi A, Orlando I, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L. Fabiani C, et al. Among authors: orlando i. Clin Rheumatol. 2018 Oct;37(10):2805-2809. doi: 10.1007/s10067-018-4133-z. Epub 2018 May 15. Clin Rheumatol. 2018. PMID: 29766375
45 results